Pfizer or Clorox: Dividend Coverage Is Not the Same as Visibility

Pfizer and Clorox both appeal to income investors because their yields are high by large-cap standards. The harder question is which company's cash flow can remain dependable after the next operating shock.

Pfizer currently has the cleaner coverage. Second-quarter results allowed management to raise the midpoint of its 2026 revenue outlook, and the dividend remains supported by cash generation. Yet several important medicines face patent expirations through 2028. Replacing that revenue requires successful launches, acquisitions and pipeline execution, all of which carry more uncertainty than a consumer-products turnaround.

Clorox faces a more visible, nearer-term problem. It produced $405 million of free cash flow in fiscal 2026 and paid $602 million in dividends. Management expects cash conversion to normalize and guides to 3.5% to 4.5% organic sales growth with adjusted EPS of $5.70 to $6.00 in fiscal 2027. Investors can track that recovery quarter by quarter through volumes, gross margin and working capital.

Pfizer's risk is harder to model because clinical results, regulation and deal integration can change the earnings path abruptly. Clorox's risk is less binary, but the present payout burden is heavier and debt increased after acquisitions.

Pfizer has better current coverage, while Clorox has the simpler demand profile. An investor choosing Pfizer is accepting a patent cliff in exchange for cash flow that works today. An investor choosing Clorox is accepting weak current coverage in exchange for a business whose products and recovery milestones are easier to observe.